Overview

A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

Status:
Enrolling by invitation
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Treatments:
Cytarabine
Etoposide
Ifosfamide
Methotrexate